Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Align Tech (ALGN – ...

Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market ...

Shares of Amgen Inc. AMGN rose 1.62% to $285.98 Friday, on what proved to be an all-around great trading session for the ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%.

In the latest trading session, Amgen (AMGN) closed at $318.65, marking a +0.47% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.62% ...

Healthcare & Pharmaceuticalscategory· April 3, 2025 US FDA approves Amgen's Uplizna as first treatment for rare immune disorder The U.S. Food and Drug Administration has approved expanded use of ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...